Abstract
A definite strategy for pulmonary nontuberculous mycobacterial (NTM) disease has not been established yet. For this reason, pulmonary physicians are frequently distressed in the clinical setting. The standard chemotherapy agents used for pulmonary Mycobacterium avium complex, the most common NTM in Japan, are clarithromycin, rifampicin, and ethambutol. In this manuscript as well as in the standard chemotherapy for pulmonary NTM disease, we review various clinical problems that are not included in the guidelines and new drugs that are expected to be launched in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 1084-1094 |
| Number of pages | 11 |
| Journal | Japanese Journal of Chest Diseases |
| Volume | 74 |
| Issue number | 10 |
| Publication status | Published - 2015 Oct 1 |
Keywords
- Drug therapy
- MAC/nontuberculous mycobacteria
- Mycobacterium avium complex
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine